financetom
Business
financetom
/
Business
/
Industrial technology seller Hurco's Q3 sales rise 7%
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Industrial technology seller Hurco's Q3 sales rise 7%
Sep 5, 2025 5:21 AM

Overview

* Hurco ( HURC ) fiscal Q3 sales rise 7% yr/yr, driven by growth in Americas, Asia Pacific

* Net loss narrows to $3.7 mln from $9.6 mln in prior year

* Orders fall 22% amid cautious capital purchase decisions, reflecting macroeconomic uncertainty

Outlook

* Hurco ( HURC ) optimistic about future profitability with strong cash position and tech investments

Result Drivers

* AMERICAS GROWTH - Sales in the Americas rose 10% due to increased shipments of Hurco ( HURC ) and Milltronics machines

* ASIA PACIFIC EXPANSION - Sales in Asia Pacific surged 48%, driven by higher sales of Takumi machines

* EUROPEAN STAGNATION - European sales remained flat, with favorable currency impacts offset by decreased shipments in France and Germany

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 Net -$3.69

Income mln

Q3 Capex $932,000

Q3 Gross $9.11

Profit mln

Q3 -$1.65

Operatin mln

g Income

Q3 -$3.13

Pretax mln

Profit

Press Release:

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Enlivex Therapeutics Gets Regulatory Nod in Israel to Begin Phase I Trial for Potential Psoriatic Arthritis Treatment
Enlivex Therapeutics Gets Regulatory Nod in Israel to Begin Phase I Trial for Potential Psoriatic Arthritis Treatment
Jul 23, 2024
09:53 AM EDT, 07/23/2024 (MT Newswires) -- Enlivex Therapeutics ( ENLV ) said Tuesday it has received authorization from the Israeli Ministry of Health to start a phase I clinical trial to assess the safety and tolerability of Allocetra after injection into an affected joint in psoriatic arthritis patients. The company said measuring the frequency and severity of adverse events...
US, Canadian pot firms eye Germany for growth as market stagnates at home
US, Canadian pot firms eye Germany for growth as market stagnates at home
Jul 23, 2024
By Sourasis Bose (Reuters) - North American cannabis firms, facing prohibitive laws, an overcrowded market and a deeply entrenched illicit sector at home are ramping up investments in Germany after the country partly legalized marijuana use. Germany, the largest medical cannabis market in Europe, decriminalized cannabis possession and small-scale home cultivation in April, making it easier for doctors to prescribe...
Arcutis Biotherapeutics Submits Supplemental New Drug Application to US FDA for Psoriasis Treatment
Arcutis Biotherapeutics Submits Supplemental New Drug Application to US FDA for Psoriasis Treatment
Jul 23, 2024
09:48 AM EDT, 07/23/2024 (MT Newswires) -- Arcutis Biotherapeutics ( ARQT ) said Tuesday that it has submitted a supplemental new drug application to the US Food and Drug Administration for Zoryve foam 0.3% to treat adults and adolescents aged 12 and above with scalp and body psoriasis. The submission is backed by positive results from a late-stage trial, a...
FTC Seeking Info From JPMorgan, Mastercard on 'Surveillance Pricing'
FTC Seeking Info From JPMorgan, Mastercard on 'Surveillance Pricing'
Jul 23, 2024
09:48 AM EDT, 07/23/2024 (MT Newswires) -- The US Federal Trade Commission said Tuesday it issued orders to JPMorgan Chase ( JPM ) , Mastercard ( MA ) , Accenture ( ACN ) and five other companies that offer surveillance pricing products and services that incorporate data about consumers' characteristics and behavior. The orders seek information about the potential impact...
Copyright 2023-2026 - www.financetom.com All Rights Reserved